An observational study in Mitochondrial Disorders, Mitochondrial Disease and Melas, sponsored by Columbia University. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Columbia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.
Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 2nd largest by planned enrollment of the 31 observational ones that give a count, is one of 7 that started in 2012, is one of 31 observational ones, reaches primary completion later than 1 of the 21 other live ones, and was the 19th registered.
189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.
Browse Mitochondrial Diseases studies →20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:
Pharming Technologies B.V. · Sites in United States, Belgium, Czechia and 6 more countries
Ages 18+
Khondrion BV · Sites in United States, Denmark, France and 4 more countries
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 8–75 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 21 · Phase 3 11 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,900 is above the median of 80 across 65 observational studies indexed under Mitochondrial Diseases.
Median enrollment 38 across the 50 interventional studies, 61 across the 31 observational. Of the 54 that completed or were terminated, 23 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 6 studies filed under Mitochondrial Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Mitochondrial Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT03639701Columbia UniversityTreatment of TK2 Deficiency With Thymidine and Deoxycytidine | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Mitochondrial Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators are studying patients with undefined mitochondrial diseases to identify genetic mutations in nuclear or mitochondrial Deoxyribonucleic Acid (DNA). Most patients with suspected or known mitochondrial diseases have no genetic confirmation. The investigators expect that evaluating tissue samples from patients with mitochondrial disorders will lead us to discover mutations in new or known genes causing mitochondrial dysfunction.
Presently, the investigators know of about 200 mitochondrial disorders. The investigators know that there are about 1,300 genes responsible for mitochondrial function. Thus, there are a lot of mutated genes to be discovered out there. Currently, most patients with suspected or known mitochondrial disorders do not have genetic confirmation of the disease.
The goal of this project is to perform biochemical and DNA analysis on tissue samples of patients with mitochondrial disorders to find new genes that might be involved in mitochondrial dysfunction.
Leftover patient tissue samples will be obtained for analysis from within the Columbia Presbyterian Medical Center. Left over patient samples may also be sent from outside the institution. This is not a "first-step" in the diagnostic process, but rather an option for evaluation in patient samples for which no known diagnosis or genetic confirmation has been made.
The research laboratory does not guarantee that a sample will be analyzed. Sample analysis is performed according to research interest. If they choose, patients can be contacted should laboratory findings provide insight into their disease.
Patients of all ages, race, gender with known or suspected mitochondrial disorders and their carrier relatives (if requested).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
Number of patients with reduced respiratory chain enzyme levels
Biochemical studies involving mitochondrial function. The levels will be compared to normal levels.
Time frame: Up to 2 years
Number of new genetic mutations
Evaluation of potential genetic interaction in clinical signs and symptoms.
Time frame: Up to 2 years
Plan to share: Yes — When applicable we will submit manuscript (s) describing the findings
Started Feb 2012 (actual). Primary completion is estimated for Dec 2026, 178 months after the start.
Of 33 observational studies under Mitochondrial Diseases, half reached primary completion within 169 months of starting (the median), counting those still running; a quarter within 26. This study's planned 178 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.